See more : Banco Santander, S.A. (BCDRF) Income Statement Analysis – Financial Results
Complete financial analysis of Cellectis S.A. (CLLS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cellectis S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- BCE Inc. (BCEPF) Income Statement Analysis – Financial Results
- Coloured Ties Capital Inc. (APEOF) Income Statement Analysis – Financial Results
- Ora Gold Limited (OAU.AX) Income Statement Analysis – Financial Results
- Narf Industries Plc (NARF.L) Income Statement Analysis – Financial Results
- Saudi Re for Cooperative Reinsurance Company (8200.SR) Income Statement Analysis – Financial Results
Cellectis S.A. (CLLS)
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 755.00K | 19.17M | 73.95M | 73.95M | 15.19M | 12.73M | 25.19M | 42.58M | 55.04M | 26.30M | 22.82M | 27.81M | 20.73M | 20.98M | 17.32M | 14.77M | 4.10M |
| Cost of Revenue | 737.00K | 1.77M | 36.28M | 36.28M | 11.39M | 2.74M | 2.62M | 1.69M | 2.71M | 3.69M | 847.86K | 2.03M | 3.26M | 1.92M | 2.33M | 1.54M | 1.48M |
| Gross Profit | 18.00K | 17.40M | 37.67M | 37.67M | 3.80M | 9.99M | 22.57M | 40.90M | 52.34M | 22.61M | 21.97M | 25.78M | 17.47M | 19.06M | 14.99M | 13.23M | 2.62M |
| Gross Profit Ratio | 2.38% | 90.76% | 50.95% | 50.95% | 25.00% | 78.49% | 89.60% | 96.04% | 95.08% | 85.97% | 96.28% | 92.70% | 84.27% | 90.84% | 86.57% | 89.56% | 63.99% |
| Research & Development | 87.65M | 97.50M | 86.95M | 86.95M | 92.04M | 76.57M | 79.23M | 74.56M | 57.30M | 17.52M | 34.44M | 25.10M | 15.95M | 16.37M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 16.81M | 17.49M | 37.87M | 44.20M | 43.02M | 47.25M | 44.75M | 41.26M | 29.78M | 15.95M | 30.49M | 0.00 | 0.00 | 0.00 | 7.97M | 5.70M | 4.28M |
| Selling & Marketing | 0.00 | 3.11M | 6.33M | 1.66M | 11.43M | 16.69M | 9.14M | 8.41M | 6.67M | 6.57M | 18.14M | 0.00 | 0.00 | 17.90M | 0.00 | 0.00 | 0.00 |
| SG&A | 16.81M | 17.49M | 44.20M | 44.20M | 43.02M | 47.25M | 44.75M | 41.26M | 29.78M | 15.95M | 30.49M | 25.83M | 26.69M | 17.90M | 7.97M | 5.70M | 4.28M |
| Other Expenses | -7.14M | -7.93M | -8.04M | -8.04M | -7.71M | -25.42M | -17.90M | -19.38M | -10.88M | -11.05M | -15.95M | 995.85K | 142.57K | 35.91K | 19.54M | 12.32M | 4.37K |
| Operating Expenses | 97.32M | 107.07M | 123.11M | 123.11M | 127.35M | 115.08M | 115.22M | 104.86M | 82.87M | 28.98M | 67.13M | 51.92M | 42.78M | 34.31M | 27.51M | 18.03M | 10.41M |
| Cost & Expenses | 98.06M | 108.84M | 159.39M | 159.39M | 138.74M | 117.82M | 117.84M | 106.54M | 85.57M | 32.68M | 67.97M | 53.95M | 46.04M | 36.23M | 29.84M | 19.57M | 11.88M |
| Interest Income | 3.61M | 1.12M | 736.00K | 1.95M | 8.34M | 16.76M | 1.97M | 44.17K | 8.25M | 384.26K | 437.74K | 477.82K | 794.50K | 645.03K | 1.79M | 1.13M | 835.44K |
| Interest Expense | 6.43M | 3.79M | 5.34M | 12.05M | 2.61M | 46.00K | 4.00K | 6.31K | 22.96K | 195.78K | 407.36K | 2.32M | 632.49K | 203.48K | 8.60K | 13.92K | 29.16K |
| Depreciation & Amortization | 18.52M | 18.44M | 14.16M | 9.82M | 6.88M | 2.38M | 3.37M | 2.21M | 1.91M | 1.67M | 45.93M | 2.42M | 804.87K | 1.58M | 368.22K | 400.92K | 852.93K |
| EBITDA | -92.64M | -76.38M | -86.46M | -34.68M | -105.09M | -93.79M | -108.08M | -65.32M | -26.21M | 370.08K | 1.17M | -26.14M | -25.31M | -12.98M | -12.25M | -3.36M | -5.99M |
| EBITDA Ratio | -12,269.67% | -467.72% | -115.54% | -115.54% | -813.38% | -825.47% | -367.83% | -150.20% | -52.00% | -16.86% | 5.13% | -93.98% | -118.21% | -61.87% | -59.13% | -21.56% | -148.45% |
| Operating Income | -106.63M | -89.67M | -85.44M | -85.44M | -123.55M | -105.09M | -92.65M | -63.96M | -30.53M | -6.38M | -80.62M | -26.14M | -25.31M | -15.25M | -13.50M | -4.80M | -7.78M |
| Operating Income Ratio | -14,122.65% | -467.72% | -115.54% | -115.54% | -813.38% | -825.47% | -367.83% | -150.20% | -55.46% | -24.25% | -353.35% | -93.98% | -122.09% | -72.68% | -77.92% | -32.48% | -189.73% |
| Total Other Income/Expenses | -16.42M | -8.94M | 6.73M | -12.05M | 8.34M | 16.76M | -11.03M | 47.00K | 8.38M | 8.63M | -3.99M | -1.90M | 172.38K | 486.77K | 812.28K | 1.10M | 810.65K |
| Income Before Tax | -123.05M | -98.60M | -97.48M | -97.48M | -115.21M | -88.33M | -103.68M | -63.92M | -22.27M | 2.25M | -81.09M | -27.87M | -25.14M | -14.76M | -11.72M | -3.68M | -6.97M |
| Income Before Tax Ratio | -16,297.48% | -514.32% | -131.82% | -131.82% | -758.47% | -693.84% | -411.63% | -150.09% | -40.47% | 8.56% | -355.39% | -100.21% | -121.26% | -70.36% | -67.66% | -24.94% | -169.96% |
| Income Tax Expense | -6.21M | 87.00K | -11.20M | -24.91M | -24.53M | 16.81M | -13.20M | -1.54M | -926.03K | 2.42M | 4.68M | 1.58M | 5.76M | -4.04M | -6.20M | -3.87M | -2.61M |
| Net Income | -101.06M | -98.69M | -86.28M | -72.57M | -90.69M | -78.69M | -99.37M | -63.92M | -22.46M | 24.32K | -84.28M | -29.45M | -30.90M | -10.72M | -5.52M | 185.15K | -4.36M |
| Net Income Ratio | -13,385.30% | -514.78% | -116.68% | -98.14% | -597.01% | -618.12% | -394.51% | -150.10% | -40.81% | 0.09% | -369.38% | -105.89% | -149.05% | -51.11% | -31.87% | 1.25% | -106.22% |
| EPS | -1.77 | -2.17 | -1.93 | -1.71 | -2.14 | -1.93 | -2.78 | -1.81 | -0.66 | 0.00 | -4.08 | -1.48 | -2.19 | -0.76 | -0.39 | 0.01 | -0.31 |
| EPS Diluted | -1.77 | -2.17 | -1.93 | -1.71 | -2.14 | -1.93 | -2.78 | -1.78 | -0.65 | 0.00 | -4.08 | -1.48 | -2.19 | -0.76 | -0.39 | 0.01 | -0.31 |
| Weighted Avg Shares Out | 57.01M | 45.55M | 44.82M | 42.50M | 42.44M | 40.77M | 35.69M | 35.29M | 34.15M | 26.07M | 20.65M | 19.94M | 14.13M | 14.13M | 14.13M | 14.13M | 14.13M |
| Weighted Avg Shares Out (Dil) | 57.01M | 45.55M | 44.82M | 42.50M | 42.44M | 40.77M | 35.69M | 35.81M | 34.52M | 26.19M | 20.65M | 19.94M | 14.13M | 14.13M | 14.13M | 14.13M | 14.13M |
Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021
• Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed orrefractory multiple myeloma patients.
Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR) T-cells and gene therapy programs for monogenic diseases, announced that it will...
Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential
Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential
The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century
Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century appeared...
CRISPR: 4 Emerging Players
CRISPR can be utilized ubiquitously as a search and replace tool allowing scientists to identify DNA sequences. The potential uses of CRISPR are numerous across a large variety of fields including agriculture, chemical, pharmaceutical, and livestock industries.
Cellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside
Cellectis S.A. is an early clinical-stage immuno-oncology biotechnology company specializing in gene-edited T-cells that express chimeric antigen receptors for treating cancer. Cellectis offers a specialization in gene-editing, enabling their CAR-T product candidates to have additional safety and efficacy attributes alongside...
Cellectis' Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities
• Four new product candidates under pre-clinical development announced; UCART20x22; the first allogeneic bi-specific CAR-T cell targeting B-cell malignancies, and three additional product candidates for solid tumors UCARTMESO (targeting Mesothelin), UCARTMUC1 (targeting Mucin 1), UCARTFAP (targeting Cancer Associated Fibroblasts)
Cellectis S.A. Reports Results from Annual Shareholders' General Meeting Held on June 1, 2021
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders' General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 1, 2021 at its head office in Paris, France.
Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T
PARIS, May 11, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells (“UCART”) in the field of immuno-oncology,...
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021
NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic chimeric antigen receptor (CAR) T-cells...
Source: https://incomestatements.info
Category: Stock Reports